ArticleFrontiers in pharmacology2025
Shengxian decoction alleviates cyclophosphamide-induced immunosuppression via improving B cell-mediated immune responses.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Yam Protects Immunocompromised Mice from Influenza Infection via the Gut-SCFA-GPCR-Immune Axis.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy is a prevalent and extensively utilized cancer treatment modality. However, it can result in immunosuppression. Shengxian Decoction (SXD) is a Traditional Chinese Medicine formula that has been demonstrated to improve immunosuppression caused by chemotherapy in clinical settings. Nevertheless, the therapeutic evaluation and mechanism of SXD in regulating immunosuppression remain unclear. The aim of this study was to ascertain the efficacy of SXD in immunocompromised mice and to elucidate the underlying immunological mechanisms. Methods: The immunosuppression mouse model was generated through the administration of cyclophosphamide for 3 days. After that, the mice were treated by SXD extracts at doses of 0.47 and 0.94 g/kg/day, respectively. The spleen, thymus and blood of mice were collected for evaluation of drug efficacy. The population of B and T cells was detected by flow cytometry. The genes regulated by SXD in spleen were identified by utilizing RNA sequencing. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment were used to analyze the signaling pathway modulated by SXD. The protein expression of B cell transcription factors was detected by the immunoblotting. The signaling pathways modulated by SXD were elucidated using transcriptomics analysis complemented by network analysis. Results: SXD treatment ameliorates decreased splenic and thymic organ indexes, as well as decreased lymphocyte number in the spleen in immunosuppressed mice. ELISA assay and flow cytometry shows that SXD promotes attenuate B-cell-mediated humoral immune responses. The RNA sequencing reveals that SXD primarily upregulates the B cell-mediated immune response and B cell receptor signaling pathway. SXD treatment upregulates the expression of B cell differentiation factors Pax5, Tcf3 and promotes splenic cell proliferation. Furthermore, SXD extract significantly inhibits hypoxia and senescence pathways in the spleen. Conclusion: SXD exerts a protective effect against CTX-induced immunosuppression by upregulating B cell immunity and inhibiting hypoxia and senescence pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.